ReviewSeminars in liver disease2019
Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9.
Review in Seminars in liver disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Organoid-guided precision hepatology for metabolic liver disease.Journal of hepatology · 2024Review
- A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23.Gastroenterology · 2023Article
- Lipid Nanoparticle Delivery of Small Proteins for PotentACS applied materials & interfaces · 2023Article
- MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities.Cell death & disease · 2022Article
- rtcisE2F promotes the self-renewal and metastasis of liver tumor-initiating cells via NScience China. Life sciences · 2022Article
- In Vivo Screen Identifies Liver X Receptor Alpha Agonism Potentiates Sorafenib Killing of Hepatocellular Carcinoma.Gastro hep advances · 2022Article
- Exploring liver cancer biology through functional genetic screens.Nature reviews. Gastroenterology & hepatology · 2021Review
- Circular RNA cia-MAF drives self-renewal and metastasis of liver tumor-initiating cells via transcription factor MAFF.The Journal of clinical investigation · 2021Article
- Insight Into the Prospects for RNAi Therapy of Cancer.Frontiers in pharmacology · 2021Review
- Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma.Hepatology (Baltimore, Md.) · 2021Review
- CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions.Life sciences · 2020Review
- The Dynamic Chromatin Architecture of the Regenerating Liver.Cellular and molecular gastroenterology and hepatology · 2020Article
- Using CRISPR/Cas9 to model human liver disease.JHEP reports : innovation in hepatology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a devastating and prevalent cancer with limited treatment options. Technological advances have enabled genetic screens to be employed in HCC model systems to characterize genes regulating tumor initiation and growth. Relative to traditional methods for studying cancer biology, such as candidate gene approaches or expression analysis, genetic screens have several advantages: they are unbiased, with no
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.